Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
<p>Abstract</p> <p>Objectives</p> <p>To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit/hyperactivity disorder (ADHD) and health-related quality of life (HR-QoL) outcomes.</p...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-12-01
|
| Series: | Child and Adolescent Psychiatry and Mental Health |
| Online Access: | http://www.capmh.com/content/4/1/30 |
| _version_ | 1818272646378291200 |
|---|---|
| author | Schacht Alexander Wehmeier Peter M Escobar Rodrigo Savill Nicola Harpin Val |
| author_facet | Schacht Alexander Wehmeier Peter M Escobar Rodrigo Savill Nicola Harpin Val |
| author_sort | Schacht Alexander |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Objectives</p> <p>To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit/hyperactivity disorder (ADHD) and health-related quality of life (HR-QoL) outcomes.</p> <p>Data Sources</p> <p>Data from five similar clinical trials of atomoxetine in the treatment of children and adolescents with ADHD were included in this meta-analysis.</p> <p>Study Selection</p> <p>Atomoxetine studies that used the ADHD Rating Scale (ADHD-RS) and the Child Health and Illness Profile Child Edition (CHIP-CE) as outcome measures were selected.</p> <p>Interventions</p> <p>Treatment with atomoxetine.</p> <p>Main Outcome Measures</p> <p>Treatment group differences (atomoxetine vs placebo) in terms of total score, domains, and subdomains of the CHIP-CE were compared across age groups, and correlations between ADHD-RS scores and CHIP-CE scores were calculated by age.</p> <p>Results</p> <p>Data of 794 subjects (611 children, 183 adolescents) were pooled. At baseline, adolescents showed significantly (p < 0.05) greater impairment compared with children in the Family Involvement, Satisfaction with Self, and Academic Performance subdomains of the CHIP-CE. Treatment effect of atomoxetine was significant in both age groups for the Risk Avoidance domain and its subdomains. There was a significant age-treatment interaction with greater efficacy seen in adolescents in both the Risk Avoidance domain and the Threats to Achievement subdomain. Correlations between ADHD-RS and CHIP-CE scores were generally low at baseline and moderate in change from baseline and were overall similar in adolescents and children.</p> <p>Conclusions</p> <p>Atomoxetine was effective in improving some aspects of HR-QoL in both age groups. Correlations between core symptoms of ADHD and HR-QoL were low to moderate.</p> |
| first_indexed | 2024-12-12T21:45:23Z |
| format | Article |
| id | doaj.art-877fc042787842a18472c4a2bb0fc383 |
| institution | Directory Open Access Journal |
| issn | 1753-2000 |
| language | English |
| last_indexed | 2024-12-12T21:45:23Z |
| publishDate | 2010-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Child and Adolescent Psychiatry and Mental Health |
| spelling | doaj.art-877fc042787842a18472c4a2bb0fc3832022-12-22T00:10:56ZengBMCChild and Adolescent Psychiatry and Mental Health1753-20002010-12-01413010.1186/1753-2000-4-30Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trialsSchacht AlexanderWehmeier Peter MEscobar RodrigoSavill NicolaHarpin Val<p>Abstract</p> <p>Objectives</p> <p>To explore the influence of age on treatment responses to atomoxetine and to assess the relationship between core symptoms of attention deficit/hyperactivity disorder (ADHD) and health-related quality of life (HR-QoL) outcomes.</p> <p>Data Sources</p> <p>Data from five similar clinical trials of atomoxetine in the treatment of children and adolescents with ADHD were included in this meta-analysis.</p> <p>Study Selection</p> <p>Atomoxetine studies that used the ADHD Rating Scale (ADHD-RS) and the Child Health and Illness Profile Child Edition (CHIP-CE) as outcome measures were selected.</p> <p>Interventions</p> <p>Treatment with atomoxetine.</p> <p>Main Outcome Measures</p> <p>Treatment group differences (atomoxetine vs placebo) in terms of total score, domains, and subdomains of the CHIP-CE were compared across age groups, and correlations between ADHD-RS scores and CHIP-CE scores were calculated by age.</p> <p>Results</p> <p>Data of 794 subjects (611 children, 183 adolescents) were pooled. At baseline, adolescents showed significantly (p < 0.05) greater impairment compared with children in the Family Involvement, Satisfaction with Self, and Academic Performance subdomains of the CHIP-CE. Treatment effect of atomoxetine was significant in both age groups for the Risk Avoidance domain and its subdomains. There was a significant age-treatment interaction with greater efficacy seen in adolescents in both the Risk Avoidance domain and the Threats to Achievement subdomain. Correlations between ADHD-RS and CHIP-CE scores were generally low at baseline and moderate in change from baseline and were overall similar in adolescents and children.</p> <p>Conclusions</p> <p>Atomoxetine was effective in improving some aspects of HR-QoL in both age groups. Correlations between core symptoms of ADHD and HR-QoL were low to moderate.</p>http://www.capmh.com/content/4/1/30 |
| spellingShingle | Schacht Alexander Wehmeier Peter M Escobar Rodrigo Savill Nicola Harpin Val Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials Child and Adolescent Psychiatry and Mental Health |
| title | Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials |
| title_full | Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials |
| title_fullStr | Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials |
| title_full_unstemmed | Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials |
| title_short | Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials |
| title_sort | differences between children and adolescents in treatment response to atomoxetine and the correlation between health related quality of life and attention deficit hyperactivity disorder core symptoms meta analysis of five atomoxetine trials |
| url | http://www.capmh.com/content/4/1/30 |
| work_keys_str_mv | AT schachtalexander differencesbetweenchildrenandadolescentsintreatmentresponsetoatomoxetineandthecorrelationbetweenhealthrelatedqualityoflifeandattentiondeficithyperactivitydisordercoresymptomsmetaanalysisoffiveatomoxetinetrials AT wehmeierpeterm differencesbetweenchildrenandadolescentsintreatmentresponsetoatomoxetineandthecorrelationbetweenhealthrelatedqualityoflifeandattentiondeficithyperactivitydisordercoresymptomsmetaanalysisoffiveatomoxetinetrials AT escobarrodrigo differencesbetweenchildrenandadolescentsintreatmentresponsetoatomoxetineandthecorrelationbetweenhealthrelatedqualityoflifeandattentiondeficithyperactivitydisordercoresymptomsmetaanalysisoffiveatomoxetinetrials AT savillnicola differencesbetweenchildrenandadolescentsintreatmentresponsetoatomoxetineandthecorrelationbetweenhealthrelatedqualityoflifeandattentiondeficithyperactivitydisordercoresymptomsmetaanalysisoffiveatomoxetinetrials AT harpinval differencesbetweenchildrenandadolescentsintreatmentresponsetoatomoxetineandthecorrelationbetweenhealthrelatedqualityoflifeandattentiondeficithyperactivitydisordercoresymptomsmetaanalysisoffiveatomoxetinetrials |